Actavia Life Sciences RASP Stock
Actavia Life Sciences Price Chart
Actavia Life Sciences RASP Financial and Trading Overview
| Actavia Life Sciences stock price | 0.0078 USD |
| Previous Close | 0.03 USD |
| Open | 0.03 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.03 - 0.03 USD |
| 52 Week Range | 0.0001 - 0.05 USD |
| Volume | 132 USD |
| Avg. Volume | 2.6K USD |
| Market Cap | 24.62M USD |
| Beta (5Y Monthly) | -59.156338 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RASP Valuation Measures
| Enterprise Value | 24.84M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Actavia Life Sciences Stock Price History
| Beta (5Y Monthly) | -59.156338 |
| 52-Week Change | 31800.00% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.05 USD |
| 52 Week Low | 0.0001 USD |
| 50-Day Moving Average | 0.009128 USD |
| 200-Day Moving Average | 0.01 USD |
RASP Share Statistics
| Avg. Volume (3 month) | 2.6K USD |
| Avg. Daily Volume (10-Days) | 67 USD |
| Shares Outstanding | 771.81M |
| Float | 746.4M |
| Short Ratio | N/A |
| % Held by Insiders | 85.19% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 3.25:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | September 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -6034.53% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -4984991 USD |
| Diluted EPS (ttm) | -0.02 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.22K USD |
| Total Cash Per Share (mrq) | 0 USD |
| Total Debt (mrq) | 220.4K USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.027 |
| Book Value Per Share (mrq) | -0.002 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -195050 USD |
| Levered Free Cash Flow (ttm) | 1.45M USD |
Profile of Actavia Life Sciences
| Country | United States |
| State | NY |
| City | New York |
| Address | 420 Lexington Avenue |
| ZIP | 10170 |
| Phone | 646 396 4087 |
| Website | https://www.rasna.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. The company is developing RASP-201, a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase, a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301, an NCE for NPM1, currently at the pre-clinical stage to treat refractory AML with reduced toxicity. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York.
Q&A For Actavia Life Sciences Stock
What is a current RASP stock price?
Actavia Life Sciences RASP stock price today per share is 0.0078 USD.
How to purchase Actavia Life Sciences stock?
You can buy RASP shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Actavia Life Sciences?
The stock symbol or ticker of Actavia Life Sciences is RASP.
Which industry does the Actavia Life Sciences company belong to?
The Actavia Life Sciences industry is Biotechnology.
How many shares does Actavia Life Sciences have in circulation?
The max supply of Actavia Life Sciences shares is 771.81M.
What is Actavia Life Sciences Price to Earnings Ratio (PE Ratio)?
Actavia Life Sciences PE Ratio is now.
What was Actavia Life Sciences earnings per share over the trailing 12 months (TTM)?
Actavia Life Sciences EPS is -0.01 USD over the trailing 12 months.
Which sector does the Actavia Life Sciences company belong to?
The Actavia Life Sciences sector is Healthcare.